Inclusion Criteria:  Confirmed acute scabies disease: detection of mites and/or mite nymphs and/or mite larvae at scabies-typical predilection sites, detected by reflected light microscopy (dermatoscopy) or light microscopy of skin samples. Age between 6 and 85 years Written informed consent of the study participant (if of age) or of all guardians (in the case of study participants who are minors < 12 years of age) or of all guardians and the study participant (in the case of study participants who are minors ≥ 12 years of age).  Exclusion Criteria:  Previous treatment with antiscabiosa in the last 14 days. Known intolerance to permethrin, other pyrethroids, chrysanthemum, ivermectin or any of the other ingredients of the study medication. Scabies crustosa Impetiginisation/eczematisation requiring in-patient treatment Body weight > 120 kg Pregnancy, lactation Immunodeficiency (of any kind, including extensive local therapy (>20% body surface area) with corticosteroids >2 weeks in the last 4 weeks or ≥ 10 mg prednisolone equivalent >7 days in the last 4 weeks- even without signs of scabies crustosa) Other serious illnesses which, in the opinion of the investigator, prevent the patient from participating in the study (including risk factors for severe COVID-19 disease in the case of SARS-CoV-2 infection). Planned systemic use of corticosteroids Planned or previous (last 4 weeks) use of systemic or cutaneous non-steroidal immunosuppressants Known or clinically suspected blood-brain barrier disruption (e.g. ABCB-1 (=MDR-1) mutation), and history of neurotoxic effects from ivermectin or other substrates/inhibitors of para-glycoprotein (P-gp) Apparent unreliability or unwillingness to cooperate. Inability to understand and comply with study instructions Known alcohol, medication or drug dependence Court/agency-ordered institutionalisation Dependence on sponsor or investigator Previous participation in a clinical trial within the last 30 days or in the same clinical trial